Emergent Biosolutions (EBS) Issues Q3 Miss
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 --0%
Revenue Growth %: +32.0%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +32.0%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q3 EPS of $0.04, $0.06 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $58.8 million versus the consensus estimate of $63.59 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Kroger meets earnings expectations, revenue tops estimates
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
